drugset / Trial / NCT01958957
A Safety Study of Ginkgolides Meglumine Injection in the Treatment of Ischemic Stroke.
Phase 4
Completed
6300 enrolled
Jiangsu Kanion Pharmaceutical Co., Ltd
Beijing Bionovo Medicine Development Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
The aim of this study is to evaluate the safety of Ginkgolides Meglumine Injection in the treatment of ischemic stroke with Syndrome of Intermingled Phlegm and Blood Stasis.
Timeline
- Start
- 2013-06
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ginkgolides Meglumine Injection | Unknown | 25 mg | Intravenous |